Integrated Pharmaceuticals, Inc. Announces its First Product Shipment FITCHBURG, Mass, Jan. 5 /PRNewswire-FirstCall/ -- Integrated Pharmaceuticals, Inc. (IntePharm) (OTC.PK: INTP) announced that in December 2004 it completed its first commercial shipment of products made at its new production facility in Fitchburg, MA. IntePharm started construction of its Fitchburg facility in the spring of 2004. The shipment of this product represents a major milestone for the Company, demonstrating the scalability of its technology, the readiness of its production facility, and the effectiveness of its sales team. Dr. Chinmay Chatterjee, Ph.D., President and CEO of IntePharm said: "We are excited about having reached this milestone. We are also in discussions with several other potential customers. These discussions are at various stages of approval and negotiations concerning sales terms and conditions." Dr. Chatterjee continued: "IntePharm takes pride in providing the highest quality products to its customers. In order to maintain these high standards, all of IntePharm's products and product ingredients must pass a series of strict quality control tests to confirm that our products meet the appropriate level of quality. Our commitment to quality is unsurpassed." About the Company IntePharm is an emerging producer of pharmaceuticals, specialty compounds and chemicals for the pharmaceutical, neutraceutical and food industries. In addition to making products, IntePharm discovers and develops more efficient and cost-effective manufacturing processes. These processes are developed using a comprehensive technology platform that combines metabolic engineering, cellular genetics, advanced bioprocess engineering, and computer simulation science. For further information please contact Dr. Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. (IntePharm), at (978) 696-0020, or visit http://www.intepharm.com/. Forward-Looking Statements Certain statements contained in this press release that are not historical facts constitute "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in general, predict, indicate or imply future results, performance or achievements and generally use words so indicative. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company and its business to be materially different from that expressed or implied by such forward-looking statements. Included in those factors are the following: our dependence on a limited number of potential customers; limited managerial experience of our executives; possible needs for additional capital; possible delays in product development and delivery schedules; deferred or lost sales because of the complex sales process prevalent in the industries that we seek to serve; increased competitive pressure; and rapid technological changes. Forward-looking statements by their very nature are uncertain. There can be no guarantee that any forward-looking statement will be fulfilled. The Company assumes no obligation to update forward-looking statements to reflect actual results or changes in or additions to the factors affecting such forward- looking statements. DATASOURCE: Integrated Pharmaceuticals, Inc. CONTACT: Dr. Chinmay Chatterjee, President and CEO of Integrated Pharmaceuticals, Inc., +1-978-696-0020 Web site: http://www.intepharm.com/

Copyright